Table 2 Measures of therapeutic efficacy of AL before and after PCR correction
Outcome | Kibaha n (%; 95% CI) | Mlimba n (%; 95% CI) | Mkuzi n (%; 95% CI) | Ujiji n (%; 95% CI) | Total n (%; 95% CI) |
|---|---|---|---|---|---|
PCR uncorrected | |||||
 Parasitaemia on day 3 | 0 (0; 0–4.5) | 2 (2.3; 0.3–8.1) | 5 (5.7; 1.9–12.9) | 4 (4.7; 1.3–11.5) | 11 (3.3;1.7–5.8) |
 ETF | 0 (0; 0–4.7) | 0 (0; 0–4.2) | 0 (0; 0–4.2) | 1 (1.1%; 0–6.2) | 1 (0.3; 0–1.7) |
 LCF | 12 (15.8; 8.4–26.0) | 2 (2.3; 0.3–8.1) | 3 (3.5; 0.7–9.9) | 4 (4.6; 1.3–11.4) | 21 (6.3; 3.9–9.4) |
 LPF | 6 (7.9; 3.0–16.4) | 11 (12.8; 6.6–21.7) | 11 (12.8; 6.6–21.7) | 19 (21.8; 13.7–32.0) | 47 (14.0; 10.5–18.2) |
 ACPR | 58 (76.3; 65.2–85.3) | 73 (84.9; 75.5–91.7) | 72 (83.7; 74.2–90.8) | 63 (72.4; 61.8–81.5) | 266 (79.4; 74.7–83.9) |
 Total for per protocol | 76 | 86 | 86 | 87 | 335 |
 Withdrawn | 0 (0.0%) | 1 (1.1) | 1 (1.1) | 1 (1.1) | 3 (0.9%) |
 Lost to follow-up | 4 (5.0%) | 1 (1.1) | 1 (1.1) | 0 (0) | 6 (1.7%) |
 Total at baseline | 80 | 88 | 88 | 88 | 344 |
PCR corrected | |||||
 ETF | 0 (0; 0–6.2) | 0 (0; 0–4.9) | 0 (0; 0–4.9) | 1 (1.6;) | 1 (0.4; 0–2.1) |
 LCF | 0 (0; 0–6.2) | 0 (0; 0–4.9) | 1 (1.4:) | 0 (0; 0–5.6) | 1 (0.4; 0–2.1) |
 LPF | 0 (0; 0–6.2) | 0 (0; 0–4.9) | 0 (0; 0–4.9) | 0 (0; 0–5.6) | 0 (0; 0–1.4) |
 ACPR | 58 (100; 93.8–100) | 73 (100; 95.1–100) | 72 (98.6; 92.6–100) | 63 (98.4; 91.6–100) | 266 (99.3; 97.3–99.9) |
 Total for per protocol | 58 | 73 | 73 | 64 | 268 |
 Withdrawn/lost to follow-up | 4 (5.0%) | 2 (2.2) | 2 (2.2) | 1 (1.1) | 9 (2.6) |
 Re-infection | 15 (18.8) | 11 (12.5) | 9 (10.2) | 20 (22.7) | 55 (16.0) |
 Unknown PCRa | 3 (3.4) | 2 (0.6) | 4 (1.2) | 3 (3.4) | 12 (3.5) |
 Total at baseline | 80 | 88 | 88 | 88 | 344 |
 KM cumulative success rate | 58 (100) | 73 (100) | 72 (98.6) | 63 (98.4) | 266 (99.3) |